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Summary
 
MHC class II molecules and invariant chain assemble at a neutral pH in the endoplasmic retic-
ulum and are transported to a low pH compartment where the invariant chain is trimmed to
the class II–associated invariant chain peptide (CLIP). For many major histocompatibility
complex class II molecules, DM is required for rapid removal of CLIP, which allows binding of
antigenic peptides. Since I-A
 
g7
 
 confers susceptibility to type I diabetes in NOD mice, the bio-
chemical requirements for peptide loading were examined using soluble I-A
 
g7
 
 expressed in in-
sect cells. I-A
 
g7
 
 formed long-lived complexes with naturally processed peptides from transferrin
and albumin, whereas several peptides that represent T cell epitopes of islet autoantigens were
poor binders. I-A
 
g7
 
–peptide complexes were not sodium dodecyl sulfate (SDS) resistant, indi-
cating that SDS sensitivity may be an intrinsic property of I-A
 
g7
 
. Complexes of I-A
 
g7
 
 and CLIP
formed at a neutral pH, but rapidly dissociated at pH 5. This rapid dissociation was due to a
poor fit of M98 of CLIP in the P9 pocket of I-A
 
g7
 
, since substitution of M98 by a negatively
charged residue greatly enhanced the stability of the complex. These biochemical properties of
I-A
 
g7
 
 result in the rapid generation of empty molecules at an endosomal pH and have a global
effect on peptide binding by I-A
 
g7
 
.
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G
 
enome-wide analyses in families with type I diabetes
and in nonobese diabetic (NOD)
 
1
 
 mice demonstrated
that multiple genes contribute to susceptibility and that the
MHC is an important susceptibility locus (1–5). In humans,
susceptibility is associated with the MHC class II region, in
particular with the DR4/DQ8 and DR3/DQ2 haplotypes.
The risk for the development of type I diabetes is particu-
larly high in subjects who carry both the DR4/DQ8 and
DR3/DQ2 haplotype or who are homozygous for either
haplotype (1, 6). It is generally thought that the DQ mole-
cules (DQ8 and DQ2) are involved in the disease process,
but particular DR4 alleles also contribute to susceptibility
(for review see reference 7). Both DQ8 and DQ2 are char-
acterized by the absence of aspartic acid at 
 
b
 
57 (alanine in
 
both alleles). The DR2/DQ6 haplotype (DQB1
 
*
 
0602)
confers dominant protection from the disease.
Two features characterize the MHC class II region of
NOD mice. NOD mice express only I-A
 
g7
 
 but not I-E
molecules, due to a deletion in the E
 
a
 
 promoter. This lack
of I-E expression is important since transgenic expression
of I-E or other I-A molecules protects from spontaneous
disease (5, 8–11). The I-A molecule of NOD mice, I-A
 
g7
 
,
has the same 
 
a
 
 chain as I-A
 
d
 
 but a unique 
 
b
 
 chain sequence.
The most striking characteristic of the I-A
 
g7
 
 
 
b
 
 chain is the
presence of histidine and serine at 
 
b
 
56 and 
 
b
 
57, instead of
proline and aspartic acid as in other murine I-A alleles (12).
Crystallographic studies of human and murine MHC class
II molecules demonstrated that 
 
b
 
57 is located in the P9
pocket of the peptide binding site. In most MHC class II
molecules, 
 
b
 
57 forms a salt bridge with 
 
a
 
76, which is miss-
ing in I-A
 
g7
 
 (13–16).
It has recently been proposed that I-A
 
g7
 
 molecules are
poor peptide binders. This hypothesis is based on the ob-
servation that only a small fraction of immunoprecipitated
I-A
 
g7
 
 molecules are SDS resistant. Also, binding experiments
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 CLIP, class II–associated invariant chain
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g7
 
with affinity-purified, detergent-solubilized I-A
 
g7
 
 molecules
demonstrated little or no binding of peptides in that study
(17). To examine the biochemical properties of I-A
 
g7
 
 in the
absence of detergent, we expressed I-A
 
g7
 
 as a soluble pro-
tein in 
 
Drosophila
 
 Schneider cells. I-A
 
g7
 
 formed long-lived
complexes with naturally processed peptides from transferrin
and serum albumin, while several peptides that represent T
cell epitopes of islet antigens were poor binders. I-A
 
g7
 
formed a complex with the class II–associated invariant chain
peptide (CLIP) at a neutral pH, but these complexes rapidly
dissociated at pH 5. These biochemical properties of I-A
 
g7
 
result in the rapid generation of empty molecules at the pH
of the peptide loading compartment and have a global effect
on peptide binding by this MHC class II molecule.
 
Materials and Methods
 
Synthetic Peptides.
 
Peptides were synthesized by Quality
Controlled Biochemicals, Inc. and subjected to quality control by
reverse-phase HPLC and mass spectrometry.
 
cDNA Constructs.
 
cDNA constructs were made by reverse
transcriptase PCR using RNA from NOD spleens. Fos and Jun
dimerization domains were attached to the 3
 
9
 
 end of the I-A
 
g7
 
 
 
a
 
and 
 
b
 
 extracellular domains, respectively, through a seven-amino
acid linker [Val-Asp-(Gly)
 
5
 
] that contained a SalI restriction site.
The cDNAs encoding the signal peptides and extracellular do-
mains of I-A
 
g7
 
 
 
a
 
 and 
 
b
 
 chains were amplified first and cloned
separately into the EcoRI/SalI site of the pRmHa-3 vector under
the control of the inducible metallothionein promoter (18). The
Fos and Jun segments were excised with SalI from similar con-
structs made for HLA-DR2 (19) and cloned into the SalI site of
these vectors (I-A
 
a
 
-Fos, I-A
 
b
 
-Jun). The orientation of the Fos
and Jun segments and the sequence of the constructs were con-
firmed by dideoxy-sequencing. The following oligonucleotides
were used for the amplification of I-A
 
a
 
 and I-A
 
b
 
 segments. For-
ward primer for I-A
 
a
 
, 5
 
9
 
 AAA AAA gAA TTC ATg CCg TgC
AgC AgA gCT CTg 3
 
9
 
; reverse primer for I-A
 
a
 
, 5
 
9
 
 AAA AAA
gTC gAC TTC TgT CAg CTC TgA CAT gg 3
 
9
 
; forward
primer for I-A
 
b
 
, 5
 
9
 
 AAA AAA gAA TTC ATg gCT CTg CAg
ATC CCC AgC 3
 
9
 
; reverse primer for I-A
 
b
 
, 5
 
9
 
 AAA AAA gTC
gAC CTT gCT CCg ggC AgA CTC ggA 3
 
9
 
. The EcoRI and
SalI sites in the forward and reverse primers, respectively, are un-
derlined.
 
Transfection of Drosophila Schneider Cells. Drosophila
 
 
 
melanogaster
 
S2 cells (4 
 
3
 
 10
 
6
 
) were transfected with 20 
 
m
 
g of each plasmid,
0.5 
 
m
 
g of hygromycin selection vector pUC-hygMT, and 20 
 
m
 
l
of liposomes (Invitrogen) in 1 ml medium without FCS for 4 h.
After transfection, cells were grown in Schneider medium (Sigma
Chemical Co.) supplemented with 10% of FCS. Selection was
performed by addition of hygromycin to a final concentration of
0.1 mg/ml. Approximately 2 wk after transfection, cells were
cloned by limiting dilution in 96-well plates. Clones were ex-
panded and tested for secretion of I-A
 
g7
 
 by Western blot analysis
after induction of expression with copper sulfate (1 mM). The
clone with the highest expression level was scaled up in roller
bottles using Schneider medium supplemented with 5% FCS and
0.1 mg/ml of hygromycin. The supernatant was harvested 4 d af-
ter induction of protein expression with copper sulfate at 1 mM
(Sigma Chemical Co.).
 
Purification of I-A
 
g7
 
.
 
Supernatants were concentrated by ul-
trafiltration using a YM30 spiral membrane cartridge (Amicon).
The I-A–specific 10-2.16 mAb (20; hybridoma from the Ameri-
can Type Culture Collection) was coupled to cyanogen bro-
mide–activated Sepharose 4B beads (Pharmacia Biotech). The
concentrated supernatant was passed through a Sepharose 4B pre-
column and the 10-2.16 column at a flow rate of 9 ml/h. The col-
umn was then washed with 100 mM phosphate buffer, pH 8.0,
and the protein was eluted with 2 bed volumes of 50 mM gly-
cine, pH 11.5. Fractions were immediately neutralized by addi-
tion of 2 M Tris, pH 8.8, and dialyzed against PBS. Protein con-
centration was determined with the Coomassie Plus protein assay
(Pierce).
 
Western Blot Analysis and HPLC Gel Filtration.
 
Antisera speci-
fic for the Fos and Jun dimerization domains were generated by
immunizing Lewis rats with synthetic peptides (provided by Dr.
P. Kim, Whitehead Institute, Cambridge, MA). Fos peptide
sequence, Ac-CGGTDTLQAETDQLEDEKYALQTEIANLLKE-
KEKL-CONH
 
2
 
; Jun peptide sequence, Ac-CGGIARLEEKVK-
TLKAQNYELASTANMLREQVAQL-CONH
 
2
 
.
For Western blot analysis, proteins were separated under
reducing conditions by SDS-PAGE (12%) and transferred to a
polyvinylidene difluoride membrane (Millipore Corp.). Mem-
branes were blocked overnight in 3% non-fat dry milk in TBST-
buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 0.2% Tween 20).
Membranes were probed with Fos antiserum (1:1,000) and/or
Jun antiserum (1:500). Bound Fos and Jun antibodies were de-
tected by incubating the membranes with horseradish peroxi-
dase–conjugated anti–rat IgG (1:3,000). The blots were devel-
oped by ECL (Amersham).
HPLC gel filtration analysis of I-A
 
g7
 
 was performed using a
Bio-Gel SEC 30-XL column (300 
 
3
 
 7.8 mm; Bio-Rad) with phos-
phate buffered saline, pH 7.8, at a flow rate of 0.8 ml/min. The
following proteins were used as molecular mass standards: thyro-
globulin (669 kD), aldolase (158 kD), BSA (67 kD), ovalbumin
(43 kD), and chymotrypsinogen A (25 kD).
 
Peptide Binding Assays.
 
Purified I-A
 
g7
 
 (0.6 
 
m
 
g) was incubated
with biotinylated test peptide at 37
 
8
 
C for 18 h in a final volume
of 50 
 
m
 
l. Buffers were either 20 mM sodium acetate/100 mM
NaCl, pH 5.0, or PBS, pH 7.4, both containing 1 mM PMSF
and 1 mM EDTA. In parallel, a 96-well plate (Fluoronunc; Nunc)
was coated overnight at 4
 
8
 
C with 50 
 
m
 
l of 10 
 
m
 
g/ml of the
I-A–specific antibody 10-2.16 in sodium bicarbonate buffer, pH
9.6. Nonspecific binding sites were blocked with 10% FCS in
PBS/0.05% Tween 20 (PBS-Tween) for 2 h at room temperature.
Wells were washed three times with PBS-Tween and I-A
 
g7
 
–pep-
tide samples were added to the wells. After a 1-h incubation,
wells were washed four times with PBS-Tween and europium-
labeled streptavidin (Wallac Oy, Finland) was added (1:2,000 in
PBS/0.5% BSA, 100 
 
m
 
l/well) for detection of I-A
 
g7
 
–bound bio-
tinylated peptide. After a 1-h incubation at room temperature,
wells were washed six times with PBS-Tween and Delfia enhance-
ment solution (Wallac Oy) was added. Fluorescence was quanti-
tated after 30 min in a fluorescence plate reader (Delfia 1234;
Wallac Oy).
For competition assays, 0.6 
 
m
 
g of soluble I-A
 
g7
 
 was incubated
with biotinylated transferrin peptide (1 
 
m
 
M) at pH 5.0 in the
presence of nonbiotinylated competitor peptide (8 nM–25 
 
m
 
M).
I-A
 
g7
 
–bound biotinylated transferrin peptide was quantitated as
described above.
 
Peptide Dissociation Experiments.
 
For CLIP and CLIP 98D
dissociation assays, soluble I-A
 
g7
 
 was loaded with biotinylated
CLIP or CLIP 98D (1 
 
m
 
M) at 37
 
8
 
C for 18 h at pH 7.4. An equal
volume of 20 mM sodium acetate, pH 4.5, or PBS, pH 7.4, was
added in the presence of nonlabeled mouse serum albumin pep- 
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tide (100 
 
m
 
M). The final pH was either 5.0 or 7.4. At different
time points (5–120 min), the reaction was stopped by freezing the
samples at 
 
2
 
20
 
8
 
C in the presence of BSA (200 
 
m
 
M). For quanti-
fication of bound biotinylated peptide, samples were mixed with
an equal volume of 40 
 
m
 
M Tris, pH 7.4, and captured with 10-2.16
antibody–coated wells at 4
 
8
 
C for 1 h. All wells were developed
by incubation for 1 h at 4
 
8
 
C with streptavidin-europium (dilution
of 1:2,000). Fluorescence was quantitated as described above.
For other peptide dissociation assays, soluble I-A
 
g7
 
 was incu-
bated with biotinylated peptide (1 
 
m
 
M) at 37
 
8
 
C for 18 h at pH 5.0
in a final volume of 50 
 
m
 
l. Then the pH of the samples was either
maintained at pH 5.0 or adjusted to pH 7.4 (by addition of Tris,
pH 8.8). Nonlabeled mouse serum albumin peptide (100 
 
m
 
M) was
added to prevent rebinding of biotinylated peptides. At different
 
time points (5 min to 72 h), reactions were stopped by freezing the
samples at 
 
2
 
20
 
8
 
C in the presence of BSA (200 mM). Bound bio-
tinylated peptides were then quantitated as described above.
Herpes Simplex Virus 2 VP16-specific T Cell Line and T Cell Pro-
liferation Assay. 7-wk-old female NOD mice were immunized
subcutaneously with 100 mg of Herpes simplex virus (HSV)-2
VP16 peptide in CFA. Draining lymph nodes were removed 10 d
after immunization and lymph node cells were seeded at 5 3 105
per well in 96-well U-bottomed plates in serum-free media
(AIM-V; GIBCO BRL) containing 5.5 3 1025 M of 2-ME.
HSV-2 VP16 peptide was added to a final concentration of 5 mM.
After 3 d of culture, the medium was replaced with RPMI sup-
plemented with 10% FCS, 5 U/ml recombinant human IL-2
(Boehringer Mannheim), 2-ME, and nonessential amino acids
(Sigma Chemical Co.). T cells were grown for 6–8 d in this me-
dia and cells were fed every third day. The T cell line was main-
tained in culture by repeated cycles of a 3-d restimulation with ir-
radiated NOD spleen cells and 5 mM HSV-2 VP16 peptide in
AIM-V, followed by a 7-d resting period in RPMI supplemented
with 10% FCS and recombinant IL-2.
T cell proliferation assays were set up in triplicates in 96-well
U-bottomed plates with 2.5 3 104 T cells and 2.5 3 105 irradi-
ated NOD spleen cells per well in AIM-V containing 2-ME. For
blocking experiments, antibodies were added to a final concen-
tration of 10 mg/ml. After 72 h of culture, 1 mCi of [3H]thymi-
dine (NEN) was added to each well and incorporated radioactiv-
ity was quantitated in a beta-scintillation counter after harvesting
of cells onto glass fiber filters (Wallac Oy).
Results
Expression and Purification of Soluble I-Ag7. Soluble I-Ag7
was expressed in Drosophila Schneider cells by replacing the
transmembrane and cytoplasmic segments of I-Aa and
I-Ab with leucine zipper dimerization domains from the
transcription factors Fos and Jun, respectively. A short,
flexible linker [Val-Asp-(Gly)5] that encoded a SalI restric-
tion site was placed between the extracellular domains of
I-Aa and I-Ab and the Fos/Jun segments (Fig. 1). Leucine
zipper dimerization domains were previously shown to
promote the assembly of HLA-DR2 and I-Ad (19, 21).
The I-Aa–Fos and I-Ab–Jun constructs were separately
cloned into the pRmHa-3 vector under the control of the
Figure 1. cDNA constructs for the expression of soluble I-Ag7. The
signal peptides and extracellular domains of I-Ag7 a and b chains were
fused in frame with the leucine zipper dimerization domains of the tran-
scription factors Fos and Jun. A short flexible linker [Val-Asp-(Gly)5] was
placed between the 39 end of the I-A a/b extracellular domains and the
Fos/Jun leucine zippers. The I-Aa–Fos and I-Ab–Jun constructs were
separately cloned into the pRmHa-3 vector under the control of the in-
ducible metallothionein promoter. These constructs were transfected into
Drosophila Schneider cells.
Figure 2. Biochemical char-
acterization of soluble I-Ag7.
I-Ag7 was purified from concen-
trated supernatants by affinity
chromatography using a mAb
specific for the I-Ab chain
(10-2.16). (A) Purified I-Ag7 was
analyzed by SDS-PAGE (12%)
and stained with Coomassie
Blue. (B) The identity of a and
b chains was confirmed by
Western blot analysis, using
polyclonal antisera raised against
the Fos and Jun leucine zipper
segments. The migration of
I-Aa–Fos and I-Ab–Jun was similar to a and b chains of HLA-DR2 expressed with these leucine zipper dimerization domains (19). (C) HPLC gel fil-
tration analysis of recombinant I-Ag7. 20 mg of I-Ag7 were separated on a Bio-Gel SEC 30-XL column (300 3 7.8 mm; Bio-Rad) with PBS at a flow rate
of 0.8 ml/min and detection at 280 nm. The following proteins were used as molecular mass markers: thyroglobulin (669 kD), aldolase (158 kD), BSA
(67 kD), ovalbumin (43 kD), and chymotrypsinogen A (25 kD).1726 pH-dependent Release of CLIP from I-Ag7
copper-inducible metallothionein promoter (18). These
constructs were cotransfected with a hygromycin selection
plasmid into S2 cells and transfectants were cloned by lim-
iting dilution after initial selection with hygromycin. Ex-
pression was induced by addition of copper sulfate to the
growth medium and the protein was purified from concen-
trated supernatants by affinity chromatography using mAb
10-2.16. The yield was z0.7–1.6 mg/liter of culture.
SDS-PAGE of the purified protein demonstrated two
bands with an apparent molecular mass of 43.3 and 33 kD
(Fig. 2 A). The identity of these bands as I-Aa–Fos and
I-Ab–Jun, respectively, was confirmed by Western blot
analysis using antisera specific for the Fos and Jun leucine
zippers (Fig. 2 B). The migration of the two chains was
similar to that observed for a and b chains of HLA-DR2
expressed with Fos/Jun dimerization domains (19). Puri-
fied I-Ag7 eluted from a HPLC gel filtration column with a
molecular mass appropriate for soluble I-Ag7 (Fig. 2 C).
Importantly, the protein did not form high molecular mass
aggregates, indicating that it was indeed soluble in the ab-
sence of detergent.
Peptide Binding by Soluble I-Ag7. Soluble I-Ag7 was used
to examine the binding of naturally processed I-Ag7 pep-
tides as well as peptides from islet autoantigens under deter-
gent-free conditions (Fig. 3, Table I). This is important be-
cause detergents can have a major effect on peptide binding
by MHC class II molecules. For example, detergents with
unbranched intermediate length hydrocarbon chains were
found to promote dissociation of CLIP from HLA-DR
(22). Two different binding assays were performed. In the
direct binding assay, biotinylated peptides were incubated
with soluble I-Ag7 and bound biotinylated peptides were
quantitated with europium-labeled streptavidin after cap-
ture of complexes with an I-A–specific antibody. In the
Figure 3. Binding of natu-
rally processed peptides and pep-
tides from islet autoantigens to
soluble I-Ag7. Binding of pep-
tides to soluble I-Ag7 was exam-
ined both in a competition assay
at pH 5 (A) and in a direct bind-
ing assay at pH 5 (B). (A) Unla-
beled peptides were used to
compete for the binding of bio-
tinylated transferrin peptide (1
mM) to purified I-Ag7. (B) In the
direct binding assay, biotinylated
peptides (1.6 nM–1 mM) were
incubated with soluble I-Ag7 (0.6
mg) at pH 5.0. I-Ag7–bound
biotinylated peptides were quan-
titated with europium-labeled
streptavidin after capture with
mAb 10-2.16. Fluorescence was
quantitated in a time-resolved
fluorometer (Delfia; Wallac Oy).
Table I. Peptides That Were Examined for Binding to Purified I-Ag7
Peptides Reference Sequences
Murine serum albumin (560–574) 23 KPKATAEQLKTVMDD
Murine transferrin (55–68) 23 GHNYVTAIRNQQEG
Human HSP60 (441–460) 41 GCALLRCIPALDSLTPANED
Human HSP60 (169–180) 42 AQVATISANGDK
Murine insulin B (9–23) 43 SHLVEALYLVCGERG
Human GAD65 (509–528) 44 IPPSLRYLEDNEERMSRLSK
Human GAD65 (247–266) 44 NMYAMMIARFKMFPEVKEKG
Human GAD65 (524–543) 44 SRLSKVAPVIKARMMEYGTT
Human CPH (362–381) 17 KNSLINYLEQIHRGVKGFVR
Human CPH (440–464) 17 YFSPAVGVDFELESFSERKEEEKEEL
HSV-2 VP16 (430–444) 34 EEVDMTPADALDDFD
Murine CLIP (86–100) PVSQMRMATPLLMRP
The naturally processed peptide from murine serum albumin (res. 560–574) was found to be the best binder for I-Ag7, both in a direct binding assay
as well as in a competition assay (see references 17, 23, 34, 41–44 for peptide sequences).1727 Hausmann et al.
competition assay, unlabeled peptides were used at different
concentrations to compete for binding of a biotinylated
transferrin peptide to I-Ag7.
A naturally processed peptide from mouse albumin (resi-
dues 560–574) was the best binder in both assays (reference
23, Fig. 3). This peptide competed for binding of the biotiny-
lated transferrin peptide at very low peptide concentrations
and also gave very high counts in the direct binding assay,
even when the concentration of the biotinylated albumin
peptide was ,100 nM. Strong binding could also be dem-
onstrated for another naturally processed peptide from
transferrin (res. 55–68), as well as for a peptide from HSP60
(res. 441–460) (Fig. 3). The murine CLIP peptide showed
little or no binding at this pH (pH 5). Several peptides that
were identified as T cell epitopes of islet antigens competed
for binding to I-Ag7 only at relatively high peptide concen-
trations, indicating that they were relatively poor binders.
This included all three peptides from GAD 65 (res. 247–
266, 509–528, and 524–543) as well as HSP60 (169–180)
and insulin (9–23). The HSP60 (169–180), insulin (9–23),
and GAD65 (249–263) peptides were also synthesized with
an NH2-terminal biotin group and tested in the direct
binding assay. These peptides gave only low counts that
were close to background (data not shown). It is important
to note that the majority of the peptides that have been de-
scribed as T cell epitopes actually represent the human
rather than the murine sequences. Since there are sequence
differences in the sequences of some of these peptides, it is
possible that some of the murine peptides are stronger
binders. The immunodominant myelin basic protein pep-
tide (MBP, Ac1-11) that induces experimental autoimmune
encephalomyelitis in mice with the H-2u haplotype is also a
low affinity binder, whereas the immunodominant T cell
epitope of MBP in mice with the H-2s haplotype (res. 87–
99) is a high affinity binder (24).
Rapid Dissociation of CLIP from I-Ag7 at an Endosomal pH.
The transferrin peptide bound to I-Ag7 at both an acidic
and a neutral pH (Fig. 4 B). The binding kinetics were
characteristic for an “empty” MHC class II molecule and
similar to those previously observed for soluble HLA-DR2
(Fig. 4 C; reference 19). In contrast, CLIP bound to I-Ag7
at a neutral pH; at an acidic pH little or no binding was de-
tected (Fig. 4 A). Analysis of human and murine CLIP pep-
tides has demonstrated a binding mode in which two me-
thionine residues of CLIP occupy the P1 and P9 pockets of
the MHC class II peptide binding site. These residues cor-
respond to positions 90 and 98 of mouse as well as residues
91 and 99 of human invariant chain, respectively (25–27).
Since the transferrin peptide carried a negative charge at
the P9 position, the corresponding residue of CLIP (me-
thionine 98) was substituted by aspartic acid (CLIP 98D).
This single amino acid substitution resulted in strong bind-
ing both at a neutral and at an acidic pH (Figs. 4 and 5).
These results demonstrated that the binding characteristics
of CLIP to I-Ag7 were due to the interaction of methionine
98 with the P9 pocket of I-Ag7.
MHC class II molecules assemble with invariant chain at
a neutral pH in the endoplasmic reticulum and are then
transported through the Golgi complex to an endosomal
compartment that has a low pH. In this compartment, the
invariant chain is proteolytically cleaved, leaving the CLIP
peptide in the binding site. The removal of CLIP is cata-
lyzed by H-2M, which allows binding of antigenic peptides
(28–32). Therefore, it was important to examine the stabil-
ity of complexes that were assembled at a neutral pH and
then shifted to an acidic pH. For that purpose, I-Ag7 was
incubated with biotinylated CLIP at a neutral pH at 378C.
An unlabeled competitor peptide was then added in order
Figure 4. Binding of CLIP and transferrin (55–68) to soluble I-Ag7.
Peptide binding to I-Ag7 was examined using biotinylated peptides that
were incubated with I-Ag7 at 378C. I-A–peptide complexes were cap-
tured with immobilized 10-2.16 mAb and the amount of biotinylated
peptide was quantitated with europium-labeled streptavidin. (A) Poor
binding of CLIP to I-Ag7 at an endosomal pH. CLIP peptide bound to
I-Ag7 at a neutral pH, but little or no binding was detected at pH 5.0.
These binding properties of CLIP were due to a poor fit of methionine
98 in the P9 pocket of I-Ag7, as substitution of this residue by aspartic acid
(CLIP 98D) greatly enhanced binding at both pH 5 and at pH 7.4. (B)
Optimal binding of transferrin peptide to I-Ag7 at endosomal pH. The
transferrin peptide bound to I-Ag7 both at pH 5.0 and at pH 7.4. Lower
peptide concentrations were required for loading of I-Ag7 at the acidic
pH. (C) Kinetics of transferrin peptide binding to I-Ag7. The transferrin
peptide (1 mM) was incubated with I-Ag7 (0.2 mM) at 378C for different
periods of time. Half-maximal loading was observed after z2 h and a pla-
teau was reached after z16 h. The kinetics of peptide binding were
therefore similar to soluble HLA-DR2 (19).1728 pH-dependent Release of CLIP from I-Ag7
to prevent rebinding of biotinylated CLIP and the pH was
changed for different periods of time (5–120 min) (Table II).
After this incubation period, the sample was neutralized
and the amount of bound biotinylated peptide was quanti-
tated. This experimental design in which complexes were
formed at a neutral pH and neutralized again after incubation
at pH 5 for different periods of time allowed the kinetics of
CLIP dissociation to be analyzed.
These experiments demonstrated that even a brief incu-
bation (5 min) at pH 5.0 before neutralization resulted in
complete dissociation of CLIP from I-Ag7 (Table II). Even
with shorter incubation times at pH 5 (,2 min), no bound
CLIP was detected (data not shown). When the complex
was kept at pH 7.4, dissociation was considerably slower
and bound CLIP was still detected after 120 min. The
rapid, pH-dependent dissociation of CLIP was due to me-
thionine 98 of CLIP, which occupies the P9 pocket of
MHC class II molecules (25). Substitution by aspartic acid
(CLIP 98D) greatly increased the stability of the complex
(Table II). These results indicated that the stability of
I-Ag7–CLIP complexes was pH dependent, and that the P9
pocket of I-Ag7 was critical in determining this property.
A possible explanation for the pH-dependent dissocia-
tion of CLIP was that the interaction of peptide side chains
with the P9 pocket was pH dependent. Therefore, a panel
of CLIP analogue peptides in which methionine 98 was
substituted by all naturally occurring amino acids was ex-
amined in the competition assay (Table III). These experi-
ments demonstrated three important properties of I-Ag7:
(i) At both an acidic and a neutral pH, I-Ag7 has a strong
preference for a negatively charged residue at P9. (ii) The
interaction of I-Ag7 and CLIP is relatively weak at a neu-
tral pH, and there is little or no interaction at an acidic pH.
Figure 5. Substitution of CLIP at the P9 position greatly enhances
binding to I-Ag7. Single amino acid analogues of CLIP were tested for
their ability to compete for binding of the biotinylated transferrin peptide
at pH 5. Although the native CLIP peptide showed little or no competi-
tion, substitution of methionine at position 98 by aspartic acid or glutamic
acid greatly increased the ability of the peptide to compete for binding.
Table II. Rapid Dissociation of CLIP from I-Ag7 at an Endosomal pH
Conditions
CLIP CLIP 98D
pH 7.4 pH 5.0 pH 7.4 pH 5.0
Fluorescence U
I-Ag7, no biotinylated peptide 462 636
Biotinylated CLIP or CLIP 98D* 58762 670032
Biotinylated CLIP or CLIP 98D plus competitor‡ 12855 775282
Additional incubation§
5 min 11190 712 750899 419044
10 min 10355 798 667831 425805
20 min 10244 813 739503 303485
30 min 8237 680 740163 342409
60 min 6783 587 788291 254762
120 min 3948 515 758073 206928
Dissociation of CLIP was examined at pH 5.0 and pH 7.4. The biotinylated CLIP peptide was first bound to I-Ag7 at a neutral pH by incubation at
37°C. The complex was then shifted to pH 5.0 for 5–120 min at 37°C and an excess of unlabelled competitor peptide was added to prevent rebind-
ing of biotinylated CLIP. The sample was then neutralized and the amount of bound biotinylated CLIP peptide was determined as described above.
Even a brief incubation at pH 5.0 resulted in complete dissociation of CLIP from I-Ag7. At pH 7.4, dissociation was significantly slower and bound
CLIP was still detectable after 2 h of incubation. Substitution of methionine 98 by aspartic acid (CLIP 98D) greatly enhanced binding, as well as the
stability of the complex at a neutral or an acidic pH.
*16 h incubation at 37°C.
‡16 h incubation at 37°C, followed by an addition of unlabeled competitor peptide.
§Additional incubation at 37°C at the indicated pH in the presence of competitor peptide, followed by neutralization of the pH 5 samples. Length of
incubation is given in min. 1729 Hausmann et al.
(iii) The interaction of some peptide side chains with the
P9 pocket is pH dependent. Particularly striking is the ob-
servation that a CLIP analogue with histidine at P9 com-
petes well at pH 7.4 (IC50 of 4 mM), but not at pH 5.0
(IC50 of .125 mM).
I-Ag7 Forms Long-lived Complexes with Naturally Processed
Peptides, But Not SDS-resistant Dimers. Since it has been
hypothesized that the interaction of peptides with I-Ag7 is
short lived (17), we determined the dissociation rates of
several peptides, which included the naturally processed
transferrin and serum albumin peptides, the CLIP 98D ana-
logue, and peptides that have been identified as T cell epi-
topes in NOD mice (Fig. 6, Table IV). Purified I-Ag7 was
first incubated with one of the biotinylated peptides (1 mM),
then the pH was adjusted to pH 7.4 or maintained at pH
5.0 and mouse serum albumin peptide was added to a fi-
nal concentration of 100 mM to prevent rebinding of dis-
sociated biotinylated peptide. The GAD 65 peptide dissoci-
ated very rapidly and a t1/2 value could not be estimated. In
contrast, complexes of I-Ag7 and several other peptides
were long lived, particularly at a neutral pH. The estimated
t1/2 value for the serum albumin peptide was .72 h and for
the transferrin peptide z45 h at pH 5.0 and .72 h at a neu-
tral pH. The dissociation of the CLIP 98D analogue was
faster, with a t1/2 value of z23 h at pH 5.0 and z70 h at
pH 7.4 (Fig. 6). These results demonstrated that I-Ag7
forms long-lived complexes with naturally processed pep-
tides and that the dissociation rate of peptides was affected
by pH.
Nevertheless, I-Ag7–peptide complexes were not resis-
tant to SDS (Fig. 7). I-Ag7 (0.6 mg) was loaded at pH 5.0
with four different peptides (transferrin, serum albumin,
CLIP, or CLIP 98D analogue) by overnight incubation at
378C. Fractions of I-Ag7–peptide complexes (0.1 mg) were
examined for the formation of SDS-resistant dimers by
Western blot analysis using polyclonal antisera specific for
the Fos and Jun segments. An SDS-resistant dimer could
not be detected with any of the peptides tested. Therefore,
the SDS assay does not determine whether peptides were
bound to I-Ag7 before addition of detergent. Soluble HLA-
DR1 expressed in insect cells forms SDS-stable dimers with
the influenza hemagglutinin (307–319) peptide (33). This
indicates that SDS-sensitivity is not a general property of
soluble MHC class II molecules expressed in insect cells.
Since several of the peptides that were identified as T cell
epitopes of islet autoantigens were poor binders, we exam-
ined if peptides with such binding properties could induce
a T cell response. We chose the peptide from HSV-2 VP16,
which has been reported to bind to HLA-DQ8 (34), since
it represented a foreign antigen. This peptide showed little
binding in the direct binding assay, but competed for bind-
ing of the biotinylated transferrin peptide at high peptide con-
centrations (data not shown). NOD mice were primed
with this peptide in CFA and a T cell line specific for the
HSV-2 peptide could be established from draining lymph
nodes by restimulation with the HSV-2 peptide (Fig. 8 A).
This T cell line was I-Ag7 restricted since the response
could be completely blocked by mAb 10-2.16, but not by a
control antibody (Y3-P) (Fig. 8 B). Stimulation of this T
cell line required the continuous presence of the peptide in
the culture. Even a single wash of the APCs after overnight
incubation with the peptide completely eliminated the T
cell response (Fig. 8 C, lane 2). These results demonstrate
that T cells from NOD mice can be primed even by a pep-
tide that is a poor binder for I-Ag7.
Discussion
Soluble I-Ag7 was used to define the biochemical require-
ments for peptide loading by this MHC class II molecule,
which confers susceptibility to type I diabetes in NOD mice.
Several peptides, including two naturally processed peptides
from exogenous antigens, bound to I-Ag7. The interaction
with the invariant chain–derived CLIP peptide was relatively
weak and pH dependent. CLIP bound to I-Ag7 at a neutral
pH, but rapidly dissociated at an endosomal pH. This prop-
Table III. pH-dependent Interaction of Different Peptide Side 
Chains with the P9 Pocket of I-Ag7
Amino acid at
position P9 of CLIP
IC50
pH 5.0 pH 7.4
mM
M .125  50
P .125 .125
G .125  10
A 15  2.0
V1 7  5 0
L .125  40
I .125 .125
F5 0  8 0
Y6 0 .125
W .125  80
H .125  4.0
K .125 .125
R .125 .125
D 0.5  0.5
E 1.6  0.4
Q .125  25
N 125  80
S2 0  4 0
T4 0 .125
C2 0  4 0
Residue 98 of CLIP was substituted by all naturally occurring amino
acids. These analogues were examined in the competition assay, at both
an acidic and neutral pH. Peptides with a negative charge at P9 com-
peted for binding both at pH 5.0 and pH 7.4 at low peptide concentra-
tions. In contrast, binding of other analogues was strongly pH depen-
dent. For example, the histidine analogue did not compete for binding
at pH 5.0, but competed well at a neutral pH.1730 pH-dependent Release of CLIP from I-Ag7
erty of CLIP was due to methionine 98, which occupies the
P9 pocket of the MHC class II peptide binding site (25).
Substitution of this residue of CLIP greatly increased the sta-
bility of the complex, both at an acidic and neutral pH.
These characteristics of I-Ag7 result in the rapid generation of
empty molecules at an endosomal pH.
Several mutant cell lines have been described that are
defective in antigen presentation due to a lack of DM
expression. In these cell lines, MHC class II–CLIP com-
plexes accumulate because DM does not catalyze the re-
moval of CLIP (32). For several human and murine MHC
class II molecules, CLIP peptides are abundant among nat-
urally processed peptides in normal cell lines, reflecting a
relatively stable interaction (35, 36). For example, CLIP
peptides have been eluted from purified I-Ab and I-Ad.
CLIP was found to bind with a relatively high affinity to
I-Ad (IC50 of 14 nM) and was one of the best binders iden-
tified for this class II molecule (36). These results are im-
portant, since I-Ag7 and I-Ad share the same I-A a chain
(12). Thus, the binding properties of CLIP to I-Ag7 appear
to be due to the unique I-Ag7 b chain.
The requirement for DM in the presentation of antigens
by I-Ag7 has been analyzed using T cell hybridomas specific
for chicken ovalbumin (37). For all T cell hybridomas, the
antigen was presented by transfectants that expressed only
I-Ag7 and invariant chain, but not H-2M, indicating that
Figure 6. pH-dependent dissociation of peptides from I-Ag7. I-Ag7 (0.6 mg) was incubated with biotinylated peptides from mouse albumin and trans-
ferrin or the CLIP 98D analogue (all at 1 mM) at 378C for 18 h at pH 5.0. The pH of the reaction was either kept at pH 5.0 (A) or adjusted to pH 7.4
(B). At this time, an excess of mouse serum albumin peptide (100 mM) was added as a competitor to prevent rebinding of biotinylated peptide. After in-
cubation at the indicated pH for 5 min to 72 h, bound biotinylated peptide was quantitated as described in Materials and Methods. All three peptides dis-
sociated slowly at a neutral pH, but dissociation of the transferrin and CLIP 98D analogue was more rapid at pH 5.0.
Table IV. I-Ag7 Forms Long-lived Complexes with
Certain Peptides
Peptide
Dissociation time (t1/2)
pH 5.0 pH 7.4
Murine serum albumin (560–574) .72 h  .72 h
Murine transferrin (55–68) z45 h  .72 h
Human HSP60 (441–460) z14 h  z25 h
Human GAD65 (249–263) not detectable not detectable
HSV-2 VP16 (430–444) not detectable not detectable
Murine CLIP not detectable z1 h
Murine CLIP 98D analogue z23 h z70 h
The dissociation time (t1/2) of a panel of peptides was examined as de-
scribed in Fig. 6. Several peptides formed long-lived complexes with
I-Ag7, particularly at a neutral pH. The peptides included the naturally
processed peptides from serum albumin and transferrin, as well as a pep-
tide from human HSP60 (res. 441–460) that has been identified as a T
cell epitope in NOD mice. The dissociation of the CLIP peptide at pH
5.0 was very rapid and a half-life could not be determined. These data
demonstrate that I-Ag7–peptide complexes can be long lived, even
though I-Ag7–peptide complexes are not SDS resistant.
Figure 7. I-Ag7/peptide complexes are not SDS-resistant. I-Ag7 (0.6 mg)
was loaded at pH 5.0 with four different peptides (transferrin, mouse se-
rum albumin, CLIP, or CLIP 98D, each at 5 mM) by overnight incuba-
tion at 378C. Fractions of I-Ag7–peptide complexes (0.1 mg) were exam-
ined for the formation of SDS-stable dimers by Western blot analysis
using polyclonal antisera specific for the Fos and Jun segments. Samples
were either not boiled (lanes 1–4) or boiled (lanes 5–8). Lanes 1 and 5,
transferrin peptide; lanes 2 and 6, mouse serum albumin peptide; lanes 3
and 7, CLIP peptide; lanes 4 and 8, CLIP 98D analogue.1731 Hausmann et al.
the murine DM homologue is not essential for antigen pre-
sentation by I-Ag7. For two out of four hybridomas with a
distinct epitope specificity, presentation was enhanced by
coexpression of H2-M. These results indicate that presen-
tation of certain epitopes by I-Ag7 can be enhanced by
H-2M. This may be due to “editing” of peptide content as
well as stabilization of empty I-Ag7 molecules by H-2M, as
described for human MHC class II molecules (30, 31, 38).
The recently solved crystal structure of I-Ad demon-
strates several features of I-A–peptide interactions that are
important in this context (16). Detailed analysis of the I-Ad
peptide binding motif demonstrated that only two peptide
residues in a 6-amino acid core were important for binding
(39). These residues are located in the P4 and P9 pockets of
the I-Ad crystal structure. I-Ad and I-Ag7 have the same a
chain sequence, but differ at 17 positions of the b chain.
An important difference is the presence of an interchain salt
bridge between b57 Asp and a76 Arg in I-Ad, which is
absent in I-Ag7 (b57 Ser). In I-Ag7–peptide complexes, a
salt bridge may instead be formed by P9 Asp or P9 Glu of
bound peptides and a76 Arg. This would explain the
strong preference for negatively charged residues at the P9
position, which was first noted among naturally processed
peptides eluted from I-Ag7 (23). In contrast, I-Ad has a pref-
erence for alanine or serine at the P9 position. An I-Ag7
peptide binding motif has been proposed, in which a pref-
erence for aliphatic residues was noted at P6 and for hydro-
phobic residues at P9 (40). Also, at P11 binding was en-
hanced by the presence of aspartic acid. It appears that these
data are in general agreement with other data on I-Ag7–
peptide interactions, provided that the relative positions are
reassigned such that these data reflect the preferences of the
P4, P7, and P9 pockets of I-Ag7.
Are I-Ag7 molecules poor peptide binders or are only
some of the peptides that have been identified thus far poor
ligands? This may be a separate issue from the lack of SDS
resistance. The analysis of soluble I-Ag7 clearly demon-
strates that this MHC class II molecule binds peptides. Two
naturally processed peptides from extracellular antigens,
mouse albumin and transferrin, are strong binders, indicat-
ing that I-Ag7 does not have a global defect in presentation
of exogenous antigens. Peptide binding by purified I-Ag7
has only been reported in two studies that used detergent-
solubilized molecules. In one of these studies, little or no
specific peptide binding could be demonstrated (17). In the
other study, high detergent concentrations (2% NP-40)
were used in the peptide binding assay (40). Binding was
demonstrated for a hen egg lysozyme peptide (res. 9–27),
but not for the mouse albumin peptide that had been
eluted from purified I-Ag7 and that represents the best
binder for soluble I-Ag7 (23). It is possible that these diffi-
culties in examining peptide binding by I-Ag7 are related to
the isolation method, in particular to the use of certain de-
tergents. The naturally processed transferrin and serum al-
bumin peptides formed long-lived complexes with I-Ag7,
in particular at a neutral pH. However, several peptides
that have been identified as T cell epitopes of islet antigens
were found to be poor binders. A similar observation has
been made in the experimental autoimmune encephalomy-
elitis model, since the immunodominant MBP peptide
(Ac1-11) in mice with the H-2u haplotype is a very weak
binder (24). Taken together, our data indicate that some
peptides form long-lived complexes with I-Ag7. However,
it is possible that a smaller fraction of I-Ag7 molecules rep-
resent long-lived class II–peptide complexes and/or that
the average affinity of I-Ag7 bound peptides is lower than
that of peptides bound to other I-A molecules.
I-Ag7 immunoprecipitated from splenocytes of NOD
mice does not form SDS-resistant dimers (17). This prop-
erty was also observed for soluble I-Ag7, even when the
molecules were loaded with peptides. Therefore, it appears
that SDS-sensitivity of the dimer is an intrinsic property of
Figure 8. NOD mice can be primed by a foreign peptide that is a weak
binder to I-Ag7. A T cell line specific for HSV-2 VP16 (res. 430–444) was
generated by immunizing NOD mice with this peptide in CFA. (A)
Dose–response of the T cell line to the HSV-2 peptide using irradiated
NOD spleen cells as APCs. T cell proliferation was determined by
[3H]thymidine incorporation. (B) The HSV-2–specific T cell line was
I-Ag7 restricted since proliferation was blocked by mAb 10-2.16 but not
by a control antibody (Y3-P). (C) Stimulation of HSV-2–specific T cells re-
quired continuous presence of the peptide. Splenocytes from NOD mice
were pulsed overnight 6 10 mM HSV-2 peptide in serum-free media
(AIM-V) and then split into four aliquots: 1, No wash of APCs before
coculture with T cells; 2, APCs washed once with 10 ml of RPMI; 3,
APCs washed twice and incubated for 30 min between washes; and 4,
APCs washed twice and incubated for 60 min between washes.1732 pH-dependent Release of CLIP from I-Ag7
I-Ag7 and does not directly reflect peptide content. SDS
sensitivity of the I-Ag7 dimer could be due to polymorphic
residues at the dimerization interface of I-Aa and I-Ab.
Mutational analysis of I-Ag7 indicated that b56 and b57 do
not determine SDS-sensitivity (17). The absence of the salt
bridge between b57 and a76 is therefore not responsible
for the lack of SDS resistance. It is also important to keep in
mind that instability of the dimer in SDS does not indicate
that the dimer is also unstable under native conditions. In
fact, analysis of I-Ag7 purified from B cells did not indicate
that the dimer was unstable in the absence of SDS (17).
The pH-dependent interaction of I-Ag7 results in the
rapid generation of empty molecules at an endosomal pH.
These results demonstrate a novel mechanism by which the
presentation of antigenic peptides can be affected by a dis-
ease-associated MHC class II molecule.
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